DISRUPT BTK II | INT | Shockwave Medical

PRIMARY

EFFECTIVENESS ENDPOINT:

Procedure success defined as ≤50% residual stenosis for all treated lesions without significant angiographic complications

DISRUPT BTK II
By The Numbers

250

Patients

40

Global sites

Lesion lengths up to 200mm

Outcomes out to 2 Years

Venita Chandra MD

Clinical Associate Professor of Surgery
Associate Program Director - Vascular Surgery
Medical Director - Stanford Advanced Wound Center

IVL in Complex CLI Cases with Ehrin Armstrong MD

Medical Director – Adventist Heart and Vascular Institute

Dr. Armstrong CLI Case: Nonhealing Wound to Right Great Toe & Non-compressible ABI

Dr. Armstrong CLI Case: Complex Intervention – Nonhealing Left 2nd, 3rd, & 4th Digits

Dr. Armstrong CLI Case: Inframalleolar Disease with Occlusion of Plantar Artery

Dr. Armstrong CLI Case: PMH of Diabetes & CKD – Nonhealing Wound of Plantar Surface of 4th Digit

Studies a real-world CLI patient population, including patients with long, calcified lesions.

Prospective, multi-center, core lab adjudicated.

Moderate-severe calcium assessed by angiography or IVUS.

IVL is the definitive treatment.

Secondary Endpoints: Primary Patency, Clinically Relevant TLF, ABI/TBI & RC, QoL, Wound Healing.

Looking for careers? Click here.